 CAMBRIDGE, Mass.BUSINESS WIREFoundation Medicine, Inc., a pioneer in molecular profiling for cancer, today announced a global collaboration with Boehringer Ingelheim to develop the companys tissue-based comprehensive genomic profiling test, FoundationOneCDx, as a companion diagnostic for Boehringer Ingelheims investigational MDM2-p53 antagonist, BI 907828, in the United States, Japan and European Union. BI 907828 is an investigational, ... Foundation Medicine Announces Global Collaborati... 